Aspirin Shows Major Benefit in Preventing Colorectal Cancer Relapse, Research Reports

An everyday dose of this common painkiller can dramatically lower the chance of certain bowel cancers coming back after operation, according to a extensive study into the preventive impact of the common drug.

European researchers discovered that people who consumed a small everyday amount of the medication after receiving cancer removal were 50% less likely to have a cancer recurrence over the next 36 months versus those who received a placebo.

The trial included participants whose tumours possessed certain gene changes that made them responsive to its cancer-fighting effects. Roughly four in ten of bowel cancer individuals display such alterations.

“I believe this will change clinical practice,” said the principal investigator. “In cases involving such genetic profiles, the chance of the cancer coming back was decreased by above a significant margin. It is a substantial effect.”

Almost millions of people are diagnosed bowel cancer every year worldwide, with more than thousands of instances in the United Kingdom. Numerous receive cancer excision, but in spite of advances in drug therapy, radiation and operations, the disease can come back if cells are not fully removed.

Rates of intestinal cancer are rising globally in adults younger than 50, and while the causes are not fully understood, researchers believe that unhealthy diets, obesity, a absence of exercise and chemicals generated by intestinal microbes are contributory.

Earlier research have demonstrated that this medication can help prevent colorectal cancer in patients who are at elevated risk due to genetic disorders such as an inherited mutation. However, it was unclear whether the medication decreased the likelihood of cancer recurring after surgery.

Investigators enrolled over 3,500 individuals who had had colorectal tumor removal at medical centers across several countries. Genetic screening on a large group of the participants revealed over 1,100, or more than a third, had changes in DNA that are part of a cellular pathway known as a gene pathway, which is associated in colorectal cancer.

The individuals with the mutations were divided to use either a low dose of medication daily or a placebo for an extended period after treatment. Those using aspirin were more than half at lower risk to have the disease come back than those on the control group, the research showed.

The drug is believed to protect against cancer by dampening inflammation, disrupting with the specific process, and limiting the behavior of clotting cells, which can encase tumour cells and potentially hide them from the patient’s defenses.

Scientists highlighted the need to run DNA analysis on each bowel cancers so that individuals who may profit from this approach could be given the medication. “This is a widely available treatment that is very inexpensive,” added.

Aspirin has been on the market for longer than a long time, but using the treatment regularly still has potential side effects. In the study, several patients suffered “severe reactions” possibly connected to the drug, such as allergic reaction, gastrointestinal bleeding and intracranial bleeding. Several individuals succumbed across both groups of the trial, with one fatality likely linked by aspirin.

A research director said: “Reducing cancer cases saves lives, and finding innovative methods to accomplish this is key to the mission to overcome cancer. There is growing evidence that in particular individuals of patients, low-dose aspirin can give protection from bowel cancer.”

“It requires bigger, rigorous research to validate which individuals would benefit the most from consuming this drug to help them have better outcomes, better quality of life, free from the concern of the disease.”